Quantcast

Industry news that matters to you.  Learn more

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient’s blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

Provista Diagnostics Announces Pivotal Clinical Results for Videssa Breast – A Simple Blood Test for Early and Accurate Breast Cancer Detection

Provista Diagnostics, Inc. recently announced that Ana Lourenco, M.D. of Rhode Island Medical Imaging, will present data from their second prospective clinical study at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, IL. Dr. Lourenco will be presenting “Proteomics at Work: Can a Protein-based Blood Assay Help Detect Breast Cancer in Women Aged 25-75 with BI-RADS® 3 or 4 Imaging Findings?” as part of the Breast Imaging (Practice Issues) Education Session. The presentation will take place on Wednesday, December 2, 2015 at 3:20 PM in meeting room E451A at the McCormick Place Lakeside Center in Chicago, IL.

Biomarkers for Chemo Resistance Could Lead to Better Breast-Cancer Treatments

Chemotherapy drugs are typically successful at killing cancerous cells during initial treatment, but some cancers develop resistance to treatment. A new study by University of Wisconsin researchers has identified how this resistance develops in some breast cancers and should lead to more patient-specific treatments.

OncoSec Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer

OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company has enrolled the first patient into a pilot biomarker trial of ImmunoPulse™ IL-12 in patients with triple negative breast cancer (TNBC). ImmunoPulse™ IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to enhance tumor immunogenicity, leading to increased tumor infiltrating lymphocytes (TILs) and pro-inflammatory cytokines.

SRI International’s Tumor Glycome Laboratory Finds Carbohydrate Biomarkers to Target Breast Cancers

The field of precision medicine acknowledges the wide variation among people and diseases. A group at SRI Biosciences, a division of SRI International, has taken another step in the direction of specific cancer diagnostics and therapy, showing for the first time that carbohydrate molecules that determine blood type can also be used to detect different forms of breast cancer, including some triple-negative breast cancer tumors.